Osteoarthritis Shoulder Injection Study

• Status: Terminated
• Trial end date: 2021-09-28
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the most effective intraarticular steroid dose for the treatment of glenohumeral osteoarthritis. The investigators aim to randomize patients into low, medium, and high dose groups of injectable corticosteroids as these doses are typically used in the standard of care for our patients. To date there has been no study to evaluate which dose is most efficient with the fewest side effects for glenohumeral osteoarthritis. The investigators objective will be to provide ultrasound guided intraarticular glenohumeral injections of these randomized concentrations and to evaluate pain and function before and following injection with the Shoulder Pain and Disability Index (SPADI). The investigators hypothesize that the low dose steroid will provide equivalent improvement of the pain and function to the medium and high doses, while minimizing side effects.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Milton S. Hershey Medical Center
• Treatments: Triamcinolone; Triamcinolone Acetonide; Triamcinolone diacetate; Triamcinolone hexacetonide

Criteria

Inclusion Criteria:

• An X-ray within a year with Radiographic evidence of OA

• 18 years of age or older

• Clinical diagnosis established due to symptoms that will include pain attributed to glenohumeral osteoarthritis, pain with range of motion, and/or functional limitations longer than 3 months.

Exclusion Criteria:

• Previous guided steroid injection of the glenohumeral joint within 3 months

• Previous diagnosis of inflammatory arthritis, rotator cuff tear, or immunocompromised

• Previous shoulder surgery

• Allergy to steroid or lidocaine

• A Kellgren and Lawrence classification of 1 or less on radiograph

• Non-English Speaking

• Inability to provide informed consent